SDC1 and cancer: Using a biomarker discovery set consisting of 302 healthy controls and 165 malignant tumor patients (Fig. 3a), we found that the plasma ofCS-CD44, -SDC1, -CSPG4, and total ofCS in all types of cancer tested were significantly higher than that in healthy controls (Fig. 3b–e).